{
  "trial_id": "NCT05111301",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, HbA1c, total daily insulin dose, duration of type 2 diabetes, type of insulin regimen (basal insulin only or MDI), use of glucagon product, ability to exercise, ability to read and understand written English, history of severe hypoglycemia, history of psychiatric treatment, history of drug or alcohol abuse, history of significant heart, lung, liver, or kidney disease, history of vision, hearing, or dexterity problems, use of specific medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, SGLT-2 inhibitors, GLP-1 receptor agonists), abnormal screening electrocardiogram, history of hemodialysis, history of adrenal insufficiency, thyroid function, presence of significant diabetes-related complications, relationship to investigative site personnel.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Hemoglobin A1c",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "total daily insulin dose",
        "duration of type 2 diabetes",
        "type of insulin regimen (basal insulin only or MDI)",
        "use of glucagon product",
        "ability to exercise",
        "ability to read and understand written English",
        "history of severe hypoglycemia",
        "history of psychiatric treatment",
        "history of drug or alcohol abuse",
        "history of significant heart",
        "lung",
        "liver",
        "or kidney disease",
        "history of vision",
        "hearing",
        "or dexterity problems",
        "use of specific medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, SGLT-2 inhibitors, GLP-1 receptor agonists)",
        "abnormal screening electrocardiogram",
        "history of hemodialysis",
        "history of adrenal insufficiency",
        "thyroid function",
        "presence of significant diabetes-related complications",
        "relationship to investigative site personnel."
      ]
    },
    "processed-gen-response": "Age, gender, HbA1c, total daily insulin dose, duration of type 2 diabetes, type of insulin regimen (basal insulin only or MDI), use of glucagon product, ability to exercise, ability to read and understand written English, history of severe hypoglycemia, history of psychiatric treatment, history of drug or alcohol abuse, history of significant heart, lung, liver, or kidney disease, history of vision, hearing, or dexterity problems, use of specific medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, SGLT-2 inhibitors, GLP-1 receptor agonists), abnormal screening electrocardiogram, history of hemodialysis, history of adrenal insufficiency, thyroid function, presence of significant diabetes-related complications, relationship to investigative site personnel."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Total Daily Insulin Dose, Type of Insulin Therapy, Frequency of Severe Hypoglycemia, Use of Glucagon Product, Exercise Frequency,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Hemoglobin A1c",
          "Baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Duration of Diabetes",
        "Total Daily Insulin Dose",
        "Type of Insulin Therapy",
        "Frequency of Severe Hypoglycemia",
        "Use of Glucagon Product",
        "Exercise Frequency"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Total Daily Insulin Dose, Type of Insulin Therapy, Frequency of Severe Hypoglycemia, Use of Glucagon Product, Exercise Frequency"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, Insulin Dose, HbA1c, BMI, History of Severe Hypoglycemia, History of Cardiovascular Disease, History of Psychiatric Treatment, History of Substance Abuse.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Hemoglobin A1c",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Diabetes Diagnosis Duration",
        "Insulin Dose",
        "BMI",
        "History of Severe Hypoglycemia",
        "History of Cardiovascular Disease",
        "History of Psychiatric Treatment",
        "History of Substance Abuse"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes Diagnosis Duration, Insulin Dose, HbA1c, BMI, History of Severe Hypoglycemia, History of Cardiovascular Disease, History of Psychiatric Treatment, History of Substance Abuse."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes, HbA1c, total daily insulin dose, type of insulin therapy (basal, MDI, CSII), history of severe hypoglycemia, history of diabetes-related complications, comorbidities (heart disease, lung disease, liver disease, chronic kidney disease, etc.), use of concomitant medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, etc.), exercise habits, smoking status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Hemoglobin A1c",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "duration of type 2 diabetes",
        "total daily insulin dose",
        "type of insulin therapy (basal, MDI, CSII)",
        "history of severe hypoglycemia",
        "history of diabetes-related complications",
        "comorbidities (heart disease, lung disease, liver disease, chronic kidney disease, etc.)",
        "use of concomitant medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, etc.)",
        "exercise habits",
        "smoking status"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes, HbA1c, total daily insulin dose, type of insulin therapy (basal, MDI, CSII), history of severe hypoglycemia, history of diabetes-related complications, comorbidities (heart disease, lung disease, liver disease, chronic kidney disease, etc.), use of concomitant medications (glucocorticoids, beta blockers, sulfonylureas, meglitinides, etc.), exercise habits, smoking status."
  }
}